Please assess the completion status of the following clinical trial:

Trial Title: Trial Investigating the Long Term Safety and Tolerability of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria (for subjects who participated in trials 000129 or 000130):~* Written informed consent prior to performance of any trial-related activity for the 000131 trial~* Has completed participation in trial 000129 or 000130~Exclusion Criteria (for subjects who participated in trials 000129 or 000130):~* Hyponatraemia (serum sodium level \<135 mmol/L) at Visit 7 in trial 000129 or 000130~* Withdrawal from clinical trial 000129 or 000130~Inclusion Criteria (for subjects who did not participate in trials 000129 or 000130):~* Written informed consent prior to performance of any trial-related activity~* Adult ≥20 years of age~* Nocturia symptoms present for ≥6 months prior to trial entry at Visit 1a~* Nocturnal polyuria at the end of screening period prior to Visit 1b~* Bothered by nocturia on the Hsu 5-point Likert bother scale at Visit 1a and Visit 1b~* Has given agreement about contraception during the trial~Exclusion Criteria (for subjects who did not participate in trials 000129 or 000130):~* Early withdrawal from clinical trial 000129 or 000130~* Evidence of any significant voiding dysfunction resulting in abnormally low bladder capacity at the end of the screening period prior to Visit 1b~* History or evidence of significant obstructive sleep apnoea~* History or diagnosis of any of the following urological diseases:~  * Interstitial cystitis or bladder pain disorder~ * In males, suspicion of moderate or severe benign prostate hyperplasia (BPH), defined as international prostate symptom score (IPSS) ≥8 points and:~    * Urinary flow \<5 mL/s or~   * Post-void residual volume \>150 mL~ * Stress urinary incontinence or mixed incontinence, where stress incontinence is the predominant component based on prior history~ * Chronic prostatitis/chronic pelvic pain syndrome~* Surgical treatment, including transurethral resection, for BOO or BPH within the past 6 months prior to Visit 1a~* Symptoms of severe over-active bladder (OAB):~  * Defined as an over-active bladder symptom score (OABSS) ≥12 at Visit 1a~ * Defined as a mean of \>8 voids and a mean of ≥1 urgency episode per 24 hours at the end of the screening period prior to Visit 1b~* Genito-urinary tract pathology that can in the investigator's opinion be responsible for urgency or urinary incontinence at Visit 1a~* Complication of cancer or a history of cancer which has not been in remission for the last 5 years at Visit 1a~* Current or a history of urologic malignancies, any lower urinary tract surgery, previous pelvic irradiation, or neoplasia at Visit 1a~* History of any neurological disease affecting bladder function or muscle strength at Visit 1a~* Habitual or psychogenic polydipsia based on medical history at Visit 1a or 24-hour urine output of \>2.8 L based on the voiding diary at Visit 1b~* Central or nephrogenic diabetes insipidus at Visit 1a~* Syndrome of inappropriate antidiuretic hormone secretion at Visit 1a~* Suspicion or evidence of cardiac failure at Visit 1a~* Uncontrolled hypertension at Visit 1a and Visit 1b~* Hyponatraemia (serum sodium level \<135 mmol/L) at Visit 1a Renal insufficiency at Visit 1a and Visit 1b~* Renal insufficiency at Visit 1a and Visit 1b~* Hepatic and/or biliary diseases at Visit 1a and Visit 1b~* Known or suspected hypersensitivity to desmopressin ODTs or previous desmopressin treatment for nocturia at Visit 1a~* In females, pregnancy, breastfeeding, or a plan to become pregnant during the period of the clinical trial.~* Known alcohol or substance abuse at Visit 1a~* Work or lifestyle that may interfere with regular night-time sleep at Visit 1a, e.g., shift workers~* Any other medical condition, laboratory abnormality, psychiatric condition, mental incapacity, or language barrier that, in the judgment of the investigator, would impair participation in the trial at Visit 1a~* Use of any prohibited therapy during the trial period

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Desmopressin ODT 25 μg (female previous on 25 μg) (Type: EXPERIMENTAL): Subjects received 25 μg in trial 000129.
- Desmopressin ODT 25 μg (female previously on placebo) (Type: EXPERIMENTAL): Subjects received placebo in trial 000129
- Desmopressin ODT 25 μg (female) (Type: EXPERIMENTAL): New female subjects
- Desmopressin ODT 25 μg (male previous on 25 μg) (Type: EXPERIMENTAL): Subjects received 25 μg in trial 000130
- Desmopressin ODT 50 μg (male previous on 50 μg) (Type: EXPERIMENTAL): Subjects received 50 μg in trial 000130
- Desmopressin ODT 50 μg (male previous on placebo) (Type: EXPERIMENTAL): Subjects received placebo in trial 000130
- Desmopressin ODT 25 μg (male) (Type: EXPERIMENTAL): Subjects received placebo in trial 000130
- Desmopressin ODT 50 μg (male) (Type: EXPERIMENTAL): New male subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).